Clinical trial
Etanercept (Enbrel®) in Psoriasis - Pediatrics
NCT00078819 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00078819 |
|---|---|
| Title | Etanercept (Enbrel®) in Psoriasis - Pediatrics |
| Official title | Placebo-controlled Multicenter Study With Etanercept to Determine Safety and Efficacy in Pediatric Subjects With Plaque Psoriasis (PEDS) |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Etanercept, Placebo |
| Enrollment | 211 |
| Start date | Sep 8, 2004 |
| Primary completion | Feb 1, 2006 |
| Completion | Jun 1, 2007 |
| First posted | Mar 9, 2004 |
| Last update posted | Jul 29, 2019 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: